News | Radiopharmaceuticals and Tracers | September 07, 2016

First Prostate Cancer Patients Imaged With Axumin (Fluciclovine F-18) Tracer at Atlanta's Northside Hospital

Recently FDA-approved PET imaging agent for patients with suspected biochemically recurrent prostate cancer now also in use at additional medical centers

Axumin, fluciclovine F-18 injection, first injection, Northside Hospital Atlanta

September 7, 2016 — Blue Earth Diagnostics announced that the first post-U.S. Food and Drug Administration (FDA) approval, commercial administrations of AxuminTM (fluciclovine F 18) injection occurred recently at Northside Hospital of Atlanta. Axumin is a novel molecular imaging agent indicated for use in positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood levels of prostate specific antigen (PSA) following prior treatment. It was recently approved by the FDA and is the first FDA-approved F-18 PET imaging agent indicated for use in patients with suspected recurrent prostate cancer.

“To date, we have had few imaging tools available for the evaluation of men with biochemically recurrent prostate cancer,” said William C. Lavely, M.D., nuclear medicine specialist, Northside Radiology Associates. “The approval of F-18 fluciclovine (Axumin) gives us an effective molecular imaging tool to evaluate these patients and assist clinicians in directing further management. Our initial experience is positive, demonstrating abnormal uptake in locations of potential metastatic prostate cancer. In my opinion, this prostate cancer PET agent, its clinical use for the evaluation of recurrent prostate cancer, and the additional information it provides for developing patient management plans has the potential to lead to better outcomes in men with recurrent prostate cancer. Further studies are necessary to determine these potential benefits.”

Axumin is commercially available through the national radiopharmacy network of Blue Earth Diagnostics’ exclusive U.S. commercial manufacturer and distributor, Siemens’ PETNET Solutions. Initial commercial production of Axumin is underway at certain regional radiopharmacies, and increasingly broader availability is planned in coming months.

Axumin was developed to enable visualization of the increased amino acid transport that occurs in many cancers, including prostate cancer. It consists of a synthetic amino acid that is preferentially taken up by prostate cancer cells compared with surrounding normal tissues, and is labeled with the radioisotope F18 for PET imaging.

For more information: www.blueearthdx.com 

Related Content

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System
News | Focused Ultrasound Therapy | March 19, 2019
EDAP TMS SA announced that Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...